PON1 and metabolic dysfunction-associated steatohepatitis: The mechanism of statins in the treatment of NASH has been demonstrated through Kupffer cells (KCs), hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs), Paraoxonase 1 (PON1), small guanine triphosphate binding proteins (GTPases), Peroxisome proliferator-activated receptors (PPARs), AMP-activated protein kinase (AMPK) and ferroptosis.